Posted by Michael Wonder on 02 Jun 2020
Lynparza recommended for approval in EU by CHMP for BRCA mutated metastatic pancreatic cancer
1 June 2020 - Only PARP inhibitor to demonstrate patient benefit in a Phase III trial in this setting.
AstraZeneca and MSD today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union for the first-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
The CHMP of the EMA based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
